# EDGAR Filing Document

**Accession Number:** 0001503802
**File Stem:** 0001193125-23-041597
**Filing Date:** 2023-2
**Character Count:** 18021
**Document Hash:** 7f307d78bc5b75390171246cc50955f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-041597.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001193125-23-041597

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**EFFECTIVENESS DATE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Karyopharm Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001503802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263931704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269845
- **FILM NUMBER:** 23640429

**BUSINESS ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
- **BUSINESS PHONE:** 617-658-0600

**MAIL ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459

**As filed with the Securities and Exchange Commission on February 17, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## Karyopharm Therapeutics Inc.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **26-3931704** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **85 Wells Avenue, 2nd Floor**<br> **Newton, MA** | **02459** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2013 Employee Stock Purchase Plan** 

**2022 Inducement Stock Incentive Plan, as amended** 

**(Full title of the plan)** 

**Richard Paulson** 

**President and Chief Executive Officer** 

**Karyopharm Therapeutics Inc.** 

**85 Wells Avenue, 2nd Floor** 

**Newton, MA 02459** 

**(Name and address of agent for service)** 

**(617) 658-0600** 

**(Telephone number, including area code, of agent for service)** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
|  Large accelerated filer | ☐ | Accelerated filer | ☒ |
|  Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**STATEMENT OF INCORPORATION BY REFERENCE** 

This Registration Statement on Form S-8 is being filed to register (a) an additional 484,848 shares of Common Stock, $0.0001 par value per share, of Karyopharm Therapeutics Inc. (the "Registrant") issuable under the Registrant's 2013 Employee Stock Purchase Plan (the "ESPP") and (b) an additional 1,200,000 shares of Common Stock issuable under the Registrant's 2022 Inducement Stock Incentive Plan, as amended (the "Inducement Plan" and, together with the ESPP, the "Plans"). Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement on Form S-8 incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-194746, filed by the Registrant with the Securities and Exchange Commission (the "SEC") on [March 21, 2014](http://www.sec.gov/Archives/edgar/data/1503802/000110465914021876/a14-8440_1s8.htm) relating to the ESPP, (ii) the Registration Statement on Form S-8, File No. 333-210221, filed by the Registrant with the SEC on [March 15, 2016](http://www.sec.gov/Archives/edgar/data/1503802/000119312516505284/d147775ds8.htm) relating to the ESPP, (iii) the Registration Statement on Form S-8, File No. 333-229971, filed by the Registrant with the SEC on [February 28, 2019](http://www.sec.gov/Archives/edgar/data/1503802/000119312519057870/d714625ds8.htm) relating to the ESPP, (iv) the Registration Statement on Form S-8, File No. 333-237160, filed by the Registrant with the SEC on [March 13, 2020](http://www.sec.gov/Archives/edgar/data/1503802/000119312520072904/d887912ds8.htm) relating to the ESPP, (v) the Registration Statement on Form S-8, File No. 333-263075, filed by the Registrant with the SEC on [February 28, 2022](http://www.sec.gov/Archives/edgar/data/1503802/000119312522057836/d316693ds8.htm) relating to the Plans and (vi) the Registration Statement on Form S-8, File No. 333-265386, filed by the Registrant with the SEC on [June 3, 2022](http://www.sec.gov/Archives/edgar/data/1503802/000119312522166718/d319784ds8.htm) relating to the Inducement Plan.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| Number | Description |
| 4.1 (1) | [Restated Certificate of Incorporation of the Registrant, as amended](http://www.sec.gov/Archives/edgar/data/1503802/000119312519215344/d760010dex31.htm) |
| 4.2 (2) | [Third Amended and Restated By-Laws of the Registrant](http://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/d423713dex31.htm) |
| 5.1 | [Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant](d265868dex51.htm) |
| 23.1 | [Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)](d265868dex51.htm) |
| 23.2 | [Consent of Ernst & Young LLP](d265868dex232.htm) |
| 24.1 | [Power of attorney (included on the signature pages of this registration statement)](#sig) |
| 99.1 (3) | [2013 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-10_6.htm) |
| 99.2 (4) | [2022 Inducement Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1503802/000095017022002548/kpti-ex10_17.htm) |
| 99.3 (5) | [Amendment No. 1 to the 2022 Inducement Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1503802/000119312522166718/d319784dex993.htm) |
| 99.4 | [Amendment No. 2 to the 2022 Inducement Stock Incentive Plan](d265868dex994.htm) |
| 107 | [Filing Fee Table](d265868dexfilingfees.htm) |

---

------

(1) Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant's Quarterly
Report on Form 10-Q (File No. 001-36167) filed with the Securities and Exchange Commission on August 7, 2019 and incorporated herein by reference.

(2) Previously filed with the Securities and Exchange Commission as Exhibit 3.1 to the Registrant's Current
Report on Form 8-K (File No. 001-36167) filed with the Securities and Exchange Commission on December 2, 2022 and incorporated herein by reference.

(3) Previously filed with the Securities and Exchange Commission as Exhibit 10.6 to the Registrant's
Registration Statement on Form S-1, as amended (File No. 333-191584) filed with the SEC on October 28, 2013 and incorporated herein by reference.

(4) Previously filed with the Securities and Exchange Commission as Exhibit 10.17 to the Registrant's
Registration Statement on Form 10-K (File No. 001-36167) filed with the Securities and Exchange Commission on March 1, 2022 and incorporated herein by
reference.

(5) Previously filed with the Securities and Exchange Commission as Exhibit 99.3 to the Registrant's
Registration Statement on Form S-8 (File No. 001-265386) filed with the Securities and Exchange Commission on June 3, 2022 and incorporated herein by
reference.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newton, Commonwealth of Massachusetts, on this 17<sup>th</sup> day of February, 2023.

---

| | |
|:---|:---|
| **KARYOPHARM THERAPEUTICS INC.** | **KARYOPHARM THERAPEUTICS INC.** |
| By: | /s/ Richard Paulson |
| Name: | Richard Paulson |
| Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES** 

We, the undersigned officers and directors of Karyopharm Therapeutics Inc., hereby severally constitute and appoint Richard Paulson, Michael Mason and Michael Mano, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Karyopharm Therapeutics Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Richard Paulson<br> Richard Paulson | President and Chief Executive Officer and Director (principal executive officer) | February 17, 2023 |
| /s/ Michael Mason<br> Michael Mason | Executive Vice President, Chief Financial Officer and Treasurer (principal financial and accounting officer) | February 17, 2023 |
| /s/ Garen G. Bohlin<br> Garen G. Bohlin | Director | February 17, 2023 |
| /s/ Barry E. Greene<br> Barry E. Greene | Director | February 17, 2023 |
| /s/ Peter Honig<br> Peter Honig, M.D., M.P.H. | Director | February 17, 2023 |
| /s/ Mansoor Raza Mirza<br> Mansoor Raza Mirza, M.D. | Director | February 17, 2023 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Christy J. Oliger<br> Christy J. Oliger | Director | February 17, 2023 |
| /s/ Deepika R. Pakianathan<br> Deepika R. Pakianathan, Ph.D. | Director | February 17, 2023 |
| /s/ Chen Schor<br> Chen Schor | Director | February 17, 2023 |

---

## Exhibit 5.1

![LOGO](g265868g0214104838149.jpg)

February 17, 2023

**Exhibit 5.1** 

Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 + 1 617 526 6000 (t) + 1 617 526 5000 (f)

Re: 2013 Employee Stock Purchase Plan

2022 Inducement Stock Incentive Plan, as amended

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 1,684,848 shares (the "Shares") of common stock, $0.0001 par value per share (the "Common Stock"), of Karyopharm Therapeutics Inc., a Delaware corporation (the "Company"), issuable under the Company's 2013 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan, as amended (collectively, the "Plans").

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

![LOGO](g265868dsp7.jpg)

------

![LOGO](g265868g0214104838149.jpg)

Karyopharm Therapeutics Inc.

February 17, 2023

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

---

| | |
|:---|:---|
| By: | /s/ Wilmer Cutler Pickering Hale and Dorr LLP |
|  | WILMER CUTLER PICKERING |
|  | HALE AND DORR LLP |

---

## Exhibit 23.2

**Exhibit 23.2** 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2013 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Karyopharm Therapeutics Inc. of our reports dated February 17, 2023, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc., and the effectiveness of internal control over financial reporting of Karyopharm Therapeutics Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

February 17, 2023

## Exhibit 99.4

**Exhibit 99.4** 

**AMENDMENT NO. 2 TO** 

**2022 INDUCEMENT STOCK INCENTIVE PLAN** 

**OF** 

**KARYOPHARM THERAPEUTICS INC.** 

The 2022 Inducement Stock Incentive Plan (the "Plan") of Karyopharm Therapeutics Inc. (the "Company") is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan):

1. Section 4(a)(1) of the Plan be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) <u>Authorized Number of Shares</u>. Subject to adjustment under Section 9, Awards may be made under the Plan for up to 2,900,000 shares of common stock, $0.0001 par value per share, of the Company (the "Common Stock"). Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.

2. Except as expressly amended herein, the Plan and all of the provisions contained therein shall remain in full force and effect.

\* \* \*

*Approved by the Board of Directors on February 10, 2023.*

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

**Form S-8** 

(Form Type)

**Karyopharm Therapeutics Inc.** 

(Exact Name of Registrant as Specified in its Charter)

**Table 1—Newly Registered Securities** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security Type | Security<br> Class<br> Title | Fee<br>Calculation<br>Rule | Amount<br>Registered(1) | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br>Aggregate Offering<br>Price | Fee<br> Rate | Amount of<br>Registration<br>Fee |
| &nbsp;&nbsp;&nbsp;Equity | Common<br> Stock, $0.0001<br> par value<br> per share | Other | 1,684,848<br> shares (2) | $3.22<br> (3) | $5425210.56<br> (3) | $110.20<br> per<br> $1,000,000 | $597.86 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts |  | $5425210.56 |  | $597.86 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $597.86 |

---

(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be
deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2) Consists of (i) 1,200,000 shares issuable under the 2022 Inducement Stock Incentive Plan, as amended and (ii)
484,848 shares issuable under 2013 Employee Stock Purchase Plan.

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the
Securities Act. The price per share and aggregate offering price are calculated on the basis of the average of the high and low prices of the registrant's common stock on the Nasdaq Global Select Market on February 10, 2023, in accordance
with Rule 457(c) under the Securities Act.